Customized "living drug" treatment for lymphoma is expected to cost $373,000 per patient

The FDA approved a second CAR-T treatment for cancer, described as gene therapy, to fight a type of B-cell lymphoma.

The FDA approved a second CAR-T treatment for cancer, described as gene therapy, to fight a type of B-call lymphoma.

U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science's Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer.

U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults.
The Food and Drug Administration allowed sales of the treatment from Kite Pharma. It uses the same technology, called CAR-T, as the first gene therapy...

U.S. regulators have approved a second gene therapy for blood cancer.

The deal is strategically important for Box as it grows its business in both the government and life sciences sectors.

TransEnterix's stock keeps moving higher in the wake of the FDA clearing its novel robotic surgery device.

Individuals with severe injuries to their extremities often develop abnormal extra-skeletal bone in damaged or healing tissue, known as heterotopic ossification (HO). This post-traumatic abnormal wound healing can interfere with recovery, causing chronic pain, reduced mobility, and impaired prosthetic limb function. Rapamycin, an FDA-approved drug already on the market, was found to dramatically reduce the presence of HO in rats, suggesting it has potential to become the first effective treatment to prevent HO.

CAR-T treatments fight cancer by genetically modifying a person’s own immune cells. A CAR-T therapy has now been approved by the FDA – but it costs $475,000